Aug. 9 (UPI) --The U.S. Food and Drug Administration on Friday announced the approval of the first nasal spray for treatment of anaphylaxis, a life-threatening allergic reaction. The epinephrine nasal ...
Intranasal epinephrine produced pharmacodynamic results that were comparable with or higher than autoinjectors and manual injection, according to a study published in Annals of Allergy, Asthma & ...
Please provide your email address to receive an email when new articles are posted on . Intranasal spray had faster and higher maximum concentrations than autoinjectors and manual syringes. The spray ...
The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.
Lidocaine, when administered via nose drops or a nasal spray, travels through the trigeminal nerve and collects in high concentrations in the teeth, jaw, and structures of the mouth, researchers from ...
On Friday, the FDA approved ARS Pharmaceuticals Inc’s (NASDAQ:SPRY) neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are ...
In a study headed by researchers at the Institute of Virology and Immunology (IVI) in Mittelhäusern, a new, two-step flu vaccination strategy that pairs intramuscular injection of a viral vectored flu ...
The U.S. Food and Drug Administration approved a new nasal spray on Friday to treat emergency allergic reactions in adults and children — the first injection-free alternative to shots like EpiPen. The ...
A drop in coronavirus incidence in Russia should not become an excuse to refuse inoculation or revaccination, Director of the Gamaleya National Research Center for Epidemiology and Microbiology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback